Boston Scientific agreed to acquire neuromodulation company Nalu Medical for $533 million to broaden its chronic pain portfolio. Nalu develops minimally invasive closed‑loop stimulation systems and leads programs aimed at persistent pain indications. The acquisition strengthens Boston Scientific’s position in interventional pain and complements its existing neuromodulation platforms. The move follows a broader industry push to consolidate neuromodulation assets and accelerate product pipelines into later‑stage clinical development and commercialization. Regulators and payers will watch clinical evidence and real‑world performance data as Boston Scientific integrates Nalu’s technology into its commercial footprint.